255 related articles for article (PubMed ID: 32977539)
41. Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.
Baader M; Bretschneider T; Broermann A; Rippmann JF; Stierstorfer B; Kuttruff CA; Mark M
Br J Pharmacol; 2018 Feb; 175(4):693-707. PubMed ID: 29197066
[TBL] [Abstract][Full Text] [Related]
42. Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice.
Dong YL; Duan XY; Liu YJ; Fan H; Xu M; Chen QY; Nan Z; Wu H; Deng SJ
Inflammation; 2019 Oct; 42(5):1530-1541. PubMed ID: 31102124
[TBL] [Abstract][Full Text] [Related]
43. Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors.
Jing T; Miao X; Jiang F; Guo M; Xing L; Zhang J; Zuo D; Lei H; Zhai X
Bioorg Med Chem; 2018 May; 26(8):1784-1796. PubMed ID: 29496411
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
45. Autotaxin inhibitors: a patent review.
Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
[TBL] [Abstract][Full Text] [Related]
46. Pharmacophoric Site Identification and Inhibitor Design for Autotaxin.
Lee MH; Lee DY; Balupuri A; Jeong JW; Kang NS
Molecules; 2019 Aug; 24(15):. PubMed ID: 31374894
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors.
Balupuri A; Lee DY; Lee MH; Chae S; Jung E; Kim Y; Ryu J; Kang NS
Bioorg Med Chem Lett; 2017 Sep; 27(17):4156-4164. PubMed ID: 28743508
[TBL] [Abstract][Full Text] [Related]
48. A rhodium(III)-based inhibitor of autotaxin with antiproliferative activity.
Kang TS; Wang W; Zhong HJ; Liang JX; Ko CN; Lu JJ; Chen XP; Ma DL; Leung CH
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):256-263. PubMed ID: 27888146
[TBL] [Abstract][Full Text] [Related]
49. Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.
Jiang N; Zhou Y; Zhu M; Zhang J; Cao M; Lei H; Guo M; Gong P; Su G; Zhai X
Eur J Med Chem; 2020 Feb; 187():111904. PubMed ID: 31806537
[TBL] [Abstract][Full Text] [Related]
50. Autotaxin-LPA axis regulates hMSC migration by adherent junction disruption and cytoskeletal rearrangement via LPAR1/3-dependent PKC/GSK3β/β-catenin and PKC/Rho GTPase pathways.
Ryu JM; Han HJ
Stem Cells; 2015 Mar; 33(3):819-32. PubMed ID: 25376707
[TBL] [Abstract][Full Text] [Related]
51. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
[TBL] [Abstract][Full Text] [Related]
52. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
53. Identification of Potent
Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
[TBL] [Abstract][Full Text] [Related]
54. Discovery and optimization of boronic acid based inhibitors of autotaxin.
Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
[TBL] [Abstract][Full Text] [Related]
55. Autotaxin inhibition: challenges and progress toward novel anti-cancer agents.
Parrill AL; Baker DL
Anticancer Agents Med Chem; 2008 Dec; 8(8):917-23. PubMed ID: 19075574
[TBL] [Abstract][Full Text] [Related]
56. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
57. Structural snapshots of the catalytic cycle of the phosphodiesterase Autotaxin.
Hausmann J; Keune WJ; Hipgrave Ederveen AL; van Zeijl L; Joosten RP; Perrakis A
J Struct Biol; 2016 Aug; 195(2):199-206. PubMed ID: 27268273
[TBL] [Abstract][Full Text] [Related]
58. ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
Schmid R; Wolf K; Robering JW; Strauß S; Strissel PL; Strick R; Rübner M; Fasching PA; Horch RE; Kremer AE; Boos AM; Weigand A
BMC Cancer; 2018 Dec; 18(1):1273. PubMed ID: 30567518
[TBL] [Abstract][Full Text] [Related]
59. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
Tabuchi S
Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
[TBL] [Abstract][Full Text] [Related]
60. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]